A5069420306- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- Cancer Research and Treatments
- Melanoma and MAPK Pathways
- Immune Cell Function and Interaction
- Pancreatic and Hepatic Oncology Research
- Cutaneous Melanoma Detection and Management
- Cancer Genomics and Diagnostics
- Pancreatitis Pathology and Treatment
- Gallbladder and Bile Duct Disorders
- CRISPR and Genetic Engineering
- Cell Image Analysis Techniques
- Monoclonal and Polyclonal Antibodies Research
- Modular Robots and Swarm Intelligence
- Neurological Complications and Syndromes
- Esophageal and GI Pathology
- Medical Malpractice and Liability Issues
- T-cell and B-cell Immunology
- Renal and Vascular Pathologies
- Bariatric Surgery and Outcomes
- Electrowetting and Microfluidic Technologies
- Renal Transplantation Outcomes and Treatments
- Tactile and Sensory Interactions
The University of Texas MD Anderson Cancer Center
2025
The University of Texas Health Science Center at Houston
2025
National Cancer Institute
2022-2025
National Institutes of Health
2022-2024
Frederick National Laboratory for Cancer Research
2024
MGH Institute of Health Professions
2024
Center for Cancer Research
2022-2023
Massachusetts General Hospital
2022
Harvard University
2022
Christiana Care Health System
2018-2020
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge for the engineering cell-based cancer immunotherapies. By mapping 55 neoantigen-specific TCR clonotypes (NeoTCRs) from 10 metastatic human tumors to their single-cell transcriptomes, we identified signatures CD8
PURPOSE Metastatic breast cancer (mBrCa) is most often an incurable disease with only modest responses to available immunotherapies. This study investigates the immunogenicity of somatic mutations in and explores therapeutic efficacy a pilot trial mutation-reactive tumor-infiltrating lymphocytes (TILs) patients metastatic disease. PATIENTS AND METHODS Forty-two mBrCa refractory previous lines treatment underwent surgical resection lesion(s), isolation TIL cultures, identification exomic...
Background The use of tumor-infiltrating T lymphocytes (TIL) that recognize cancer neoantigens has led to lasting remissions in metastatic melanoma and certain cases epithelial cancer. For the treatment latter, selecting cells for therapy typically involves laborious screening TIL recognition autologous tumor-specific mutations, detected through next-generation sequencing freshly resected tumors. Our study explored feasibility using archived formalin-fixed, paraffin-embedded (FFPE) primary...
Abstract Purpose: Immune checkpoint blockade (ICB) agents and adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) are prominent immunotherapies used for the treatment advanced melanoma. Both therapies rely on activation that target shared tumor antigens or neoantigens. Recent analysis patients with metastatic melanoma who underwent TIL ACT at NCI demonstrated decreased responses in previously treated anti–PD-1 agents. We aimed to find a basis difference response rates...
<title>Abstract</title> Adoptive cell transfer (ACT) using neoantigen reactive T lymphocytes can mediate cancer regression. Here, we developed methods to isolate unique, personalized, receptors (TCRs) from tumor infiltrating (TIL) patients with metastatic gastrointestinal cancers and incorporate the TCR α β chains into gamma retroviral vectors. We transduced autologous peripheral blood (PBL) γ-retroviruses adoptively transferred those cells after lymphodepleting chemotherapy. treated 7...
<div>AbstractPurpose:<p>Immune checkpoint blockade (ICB) agents and adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) are prominent immunotherapies used for the treatment advanced melanoma. Both therapies rely on activation that target shared tumor antigens or neoantigens. Recent analysis patients with metastatic melanoma who underwent TIL ACT at NCI demonstrated decreased responses in previously treated anti–PD-1 agents. We aimed to find a basis difference...
Abstract Adoptive cell therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most arise from rare mutations, requiring highly individualized treatments. To broaden the applicability of ACT neoantigens, we focused on TP53 mutations commonly shared across different cancer types. Here, describe a library T receptors (TCRs) that target among 7.3% solid cancers. These TCRs recognized tumor cells mutation- and human leucocyte antigen (HLA)-specific...
<div>AbstractPurpose:<p>Immune checkpoint blockade (ICB) agents and adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) are prominent immunotherapies used for the treatment advanced melanoma. Both therapies rely on activation that target shared tumor antigens or neoantigens. Recent analysis patients with metastatic melanoma who underwent TIL ACT at NCI demonstrated decreased responses in previously treated anti–PD-1 agents. We aimed to find a basis difference...